Zhitong Finance App News, Olin Biotech (688319.SH) issued an announcement. Recently, the company was concerned about false statements about the company's recombinant Staphylococcus aureus vaccine (hereinafter referred to as “recombinant Staphylococcus aureus vaccine”) phase III clinical trial data on individual online platforms. After verification, the data used in the “Recombinant Staphylococcus aureus Vaccine (RFSAV) Phase III Clinical Data Audit Report” distributed online, such as the number of confirmed cases and the total number of subjects, and their findings are not consistent with the actual situation of the company's clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.